Peptide-based COVID-19 vaccine - 21/04/2022

CoVac-1: T-cell activator against COVID-19

Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.

ProteinDistillery GmbH - 20/04/2022

Using microorganisms to create a source of sustainable protein

Yeast has been part of the human diet for thousands of years. ProteinDistillery GmbH now wants to revolutionise the environmentally friendly protein suppliers market by introducing brewer's yeast and secure the protein supply of the future.

pre-start-up company Wheyfinery - 13/04/2022

Acid whey as a valuable raw material for platform chemicals and more

There is not much you can do with acid whey, which is why several million litres of it are disposed of every year. This is both costly and not sustainable. However, researchers at Tübingen University have shown: acid whey can be used to produce precursors for biofuels, fine chemicals and antimicrobial livestock feed additives. They have set up the pre-start-up company Wheyfinery in an endeavour to make their scalable biorefinery concept…

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is funding a new Emmy Noether junior research group at the DKFZ for six years with a total of around 2 million euros. The scientists and doctors, who are part of the Clinical Cooperation Unit for Pediatric Leukemia at the KiTZ, are using a new procedure to investigate how cancer cells manipulate the formation of proteins to become resistant to cancer drugs.

Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda.

COVIC-19 clinical trial - 07/04/2022

Convalescent plasma for COVID-19 therapy: clinical trial should bring clarity

Does it help to treat COVID-19 sufferers with antibodies from people who have recovered from the disease? It seems an obvious idea and has been tested thousands of times. However, there is not yet enough evidence to prove the clinical efficacy of treating COVID-19 patients with convalescent plasma. The transfusion physician Prof. Dr. Hubert Schrezenmeier from Ulm is planning to carry out a follow-up clinical trial to find the missing evidence.

The University of Stuttgart is contributing to innovations for climate protection as part of the EU project "Smart Circular Bridge". An old material is being rediscovered: flax has been with us for thousands of years in the form of clothing, sacks, and robust ship's ropes. Now the plant fibres are experiencing a renaissance and could become the building material of the future.

Filament winding technology for sustainable construction - 06/04/2022

Robotic building with natural fibres

One of the greatest challenges in the construction industry is the transition to more environmentally friendly and resource-saving buildings. Researchers at the University of Stuttgart are combining state-of-the-art robotic filament winding technologies with ancient local crops to produce stable and sustainable lightweight structures from flax fibres.

European collaborative project led by the University of Hohenheim shows: Combining bioethanol production with carbon storage can effectively reduce CO2.

On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.

ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.

Junior Professor Dr Daniela Duarte Campos has been awarded a substantial grant from the Federal Ministry of Education and Research (BMBF). She and her junior research group are investigating bioprinting for tissue and organ engineering at the Center for Molecular Biology of Heidelberg University and at the “3D Matter Made to Order” Cluster of Excellence, a collaboration between Ruperto Carola and Karlsruhe Institute of Technology (KIT).

The "carbonauten minus CO2 factory 1" will start production of 4,000 t of CO2-reducing plastic granules annually at favorable prices in summer 2022.

Laboratory studies of lung tissue usually require the removal of large amounts of human or animal tissue. Now scientists from the University of Freiburg’s Faculty of Medicine have succeeded in collaboration with American researchers in generating tiny quantities of lung tissue, so-called organoids, from just a few body cells in the lab.

Lentil cultivation and cleaning on the farm - EIP-AGRI Rhizo-Linse project - 16/03/2022

Lentils return to the Heckengäu region

Lentils are among the oldest crop plants in Central European agriculture and were once a popular food in ancient Egypt, Persia and Mesopotamia. The legume was widespread in Germany until the mid-20th century, but has since disappeared completely from farmers’ fields. Over the past decade, lentils have reappeared as a crop grown locally and are cultivated in harmony with nature.

SolidCAR-T project - 15/03/2022

Modular ‘mini-factories’ for decentralised production of CAR T cells

Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.

Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).

Inspiration, innovation, networking are the name of the game on April 12, 2022, when the trinational event “Innovation Day Upper Rhine” (IDUR) takes place at the Palais Universitaire on the University of Strasbourg campus. Twelve universities in the Upper Rhine region, including the University of Freiburg and 100 partner companies of the EU funded project “Knowledge Transfer Upper Rhine” (KTUR), invite to a day of exchange and meeting.

Alternative foodstuff ? - 09/03/2022

Hemp: regional superfood and valuable source of protein

If there were a competition for the ‘crop of the future’, hemp would certainly be at the top. But not because of the intoxicating effect of some hemp varieties. Cannabis has the potential to help supply protein in the quantities required by a growing world population – in a sustainable way. The TASTINO project brings together researchers from academia and industry to work on ways to make the regional superfood available as a vegan alternative.

In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?

Elastin as artificial muscle material - 02/03/2022

Artificial muscle from proteins for diverse future applications

As far as diversity and complexity are concerned, proteins are nature's smallest marvels. Biotechnologists have already used natural proteins as a basis for the development, bespoke design and production of artificial systems. This is what the livMatS cluster of excellence at the University of Freiburg has been doing. Researchers in the cluster have successfully produced an artificial muscle from elastin that functions autonomously.